Osmetech has named Daryl Faulkner to be non-executive chairman. The company’s current chairman, Gordon Hall, will step down but will remain on the board as a non-executive director.
Faulkner recently was president and CEO of Digene, and he was a senior vice president and general manager for strategic business and international operations at Invitrogen.
Osmetech also said that Bruce Huebner has retired from the company and has left his position as a director.
Alan Guttmacher last week became acting director at the National Human Genome Research Institute after former director Francis Collins officially stepped down.
After 15 years as director of the institute, Collins announced two months ago that he planned to leave NHGRI to dedicate some time to “writing, reflection, and exploration of other professional opportunities in the public or private sectors.”
Guttmacher is a pediatrician and medical geneticist. He has held leadership jobs at NHGRI for nearly a decade and has been deputy director for around six years.
Before he was deputy director, Guttmacher was NHGRI’s senior clinical advisor to the director and was director of the Office of Policy, Communications, and Education.
The National Institutes of Health will “conduct a broad search” for Collins’ replacement, NHGRI said, but details of that search process remain to be finalized.
"NHGRI and its collaborators, both at the NIH and throughout the biomedical research community, are moving ahead with our historic efforts to understand the intricacies of the human genome and how it functions,” Guttmacher said in a statement.